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Tanacetum parthenium (feverfew) is an herb that is commercialized worldwide as a therapeutic treatment 
for migraine. Its pharmacological effect is mainly due to the presence of the sesquiterpene lactone 
parthenolide as well as of flavonoids. So far, there are no studies on standardization of pre-formulations 
or phytomedicines containing this herb. The present study aimed at developing a pre-formulation using 
a standardized spray-dried extract of feverfew and further designing and standardizing enteric coated 
tablets. In this work, the spray-dried extract of feverfew was evaluated for its parthenolide, santin and 
total flavonoid content, parthenolide solubility, particle size, tapped density, hygroscopicity, angle of 
repose and moisture content. Tablets containing the spray-dried extract were tested for their average 
weight, friability, hardness, and disintegration time. The total flavonoid and parthenolide contents in 
the spray-dried extract were 1.31 % and 0.76% w/w, respectively. The spray-dried extract presented 
consistent pharmacotechnical properties and allowed its tableting by direct compression. Tablet properties 
were in accordance with the proposed specifications. The procedures described herein can be used to 
prepare and evaluate pre-formulations of feverfew with adequate properties for the development of a 
high-quality phytomedicine. 
Uniterms: Enteric coated tablets. Flavonoids. Parthenolide. Phytomedicine. Spray-dried extract. 
Tanacetum parthenium.
Tanacetum parthenium (tanaceto) é uma planta medicinal comercializada no mundo todo para tratamento 
de enxaqueca. Seu efeito farmacológico é creditado principalmente à lactona sesquiterpênica partenolídeo 
e flavonóides. Até o momento não existem estudos sobre a padronização de pré-formulações ou o 
desenvolvimento de fitoterápicos com tanaceto. Logo, o objetivo deste trabalho foi obter comprimidos 
de revestimento entérico a partir de extrato seco e padronizado de tanaceto. Neste trabalho, o extrato seco 
do tanaceto obtido pelo método de spray drying foi avaliado quanto ao teor de partenolídeo, presença da 
santina, teor de flavonóides totais, solubilidade do partenolídeo, tamanho de partícula, ângulo de repouso, 
densidade, análise higroscópica e teor de umidade. A partir do extrato seco obtiveram-se comprimidos 
que foram revestidos em leito de jorro. Os comprimidos revestidos foram avaliados com relação ao peso 
médio, friabilidade, dureza e desintegração. O teor de flavonóides totais e de partenolídeo no extrato seco 
foram 1,31% e 0,76% (p/p), respectivamente. O extrato seco apresentou características farmacotécnicas 
satisfatórias permitindo a obtenção de comprimidos pelo método de compressão direta. As propriedades 
dos comprimidos revestidos estão de acordo com as especificações da literatura. Os procedimentos 
utilizados nesse trabalho podem ser utilizados para obter extrato seco e fitoterápicos de T. parthenium 
com alto padrão de qualidade.
Unitermos: Comprimidos de revestimento entérico. Extrato seco. Fitoterápicos. Flavonóides. 
Partenolídeo. Tanacetum parthenium.
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INTRODUCTION
Herbal medicines have a long history of traditional 
use and play an important role in the primary health 
care of developing countries (Calixto, 2000). Nonethe-
less, in many developed countries, herbal medicinal 
products – or phytomedicines – are widely used and 
retail sales surpass billions of dollars (Barnes, 2003). 
The aerial parts of feverfew [Tanacetum parthenium L. 
Shultz Bip., Asteraceae] have been used since ancient 
times for a variety of medicinal purposes because of its 
anti-inflammatory, analgesic and antipyretic properties. 
Nowadays it is a recommended therapeutic treatment for 
migraine prophylaxis (Khan et al., 2003). Although the 
pathophysiology of migraine is not yet fully understood, 
its symptoms are reported by 15% of females and 6% 
of males in the adult age, from 35 to 45 years (Pfaffen-
rath, 2002). Clinical trials have demonstrated the high 
effectiveness of feverfew against headache and other 
symptoms linked to migraine (Palevith, 1997). Amongst 
feverfew constituents are sesquiterpene lactones, flavo-
noids and spiroketal enol ethers (Bolhmann, Zdero, 1982; 
Long et al., 1999; Williams et al., 2003). Parthenolide, 
a sesquiterpene lactone, is the major constituent of the 
herb and accounts for many of its biological activities. 
For instance, it has been shown that parthenolide presents 
in vitro inhibitory effect on the release of serotonin from 
blood platelets (Vogler, 1998; Weber et al., 1997), in 
vivo antinociceptive and anti-inflammatory effects and 
in vitro and in vivo inhibition of several eicosanoids 
(Hwang et al., 1996; Fukuda, 2000; Kwok et al., 2001). 
Furthermore, other studies have shown that the feverfew 
flavonoids also present anti-inflammatory activity (Long 
et al., 1999; Williams et al., 2003).
Parthenolide is usually employed as a chemical 
marker in quality control of feverfew products. Due to the 
importance of this compound, besides the evaluation of 
its biological activities, many studies describing its quan-
tification by HPLC methods have been published (Zhou 
et al., 1999; Abourashed, Khan, 2000). 
Despite of its importance in the herbal medicine 
market, several feverfew products are still sold as hard 
gelatine capsules containing grinded aerial parts of the 
plant, which substantially increases the difficulties of 
standardization and quality control as well as the es-
tablishment of therapeutic effectiveness of this herbal 
medicine.
Over the last few years, the industrial manufacture of 
phytomedicines has grown considerably. For this reason, 
organizations like the World Health Organization (WHO), 
the European Union (EU) and the European Scientific 
Co-operative on Phytotherapy (ESCOP) have been de-
manding regulatory guidelines and conclusive studies 
on chemical, physical and pharmacological properties of 
herbal drugs for their approval (Barnes, 2003; Silano et 
al., 2004). Moreover, the market demand for plant medi-
cines is based on reliable products, obtained by validated 
methods and standardized. One of the most used methods 
for extracts stabilization and standardization is the spray 
drying using technological carriers (Senna et al., 1997; 
Linden et al., 2000).
Dry extracts show a number of advantages over the 
conventional fluid forms, including higher amounts of 
active compounds, higher stability, easier standardization 
and quality control, which therefore increase the therapeu-
tic efficacy and product value (Runha et al., 2001). Fur-
thermore, the design and formulation of herbal medicine 
tablets is a challenging task due to poor tableting properties 
of plant extracts (Palma et al., 2002).
Therefore, the aim of the present study was to de-
velop enteric coated tablets of feverfew using its spray 
dried extracts.
MATERIAL AND METHODS
Chromatographic standards
Parthenolide was isolated from Talauma ovata ST. 
HIL (Magnoliaceae) according to a previously reported 
method (Stefanello, Alvarenga, 1997). 
Santin was isolated from the T. parthenium powder 
(aerial parts) according to a previously reported method 
(Chaves, Da Costa, 2008). 
Solvents, reagents and pharmaceutical excipients
Solvents for HPLC analysis (HPLC grade) were 
supplied by Mallinckrodt Baker (USA); solvents for UV 
analysis, reagents and salts were supplied by Merck (Rio 
de Janeiro, Brazil). The water was purified using a Milli-Q 
system (Millipore®, USA). Phosphate buffer pH 7.5 and 
HCl buffer pH 1.2 were prepared according to the United 
States Pharmacopoeia (1995) specifications. The phar-
maceutical ingredients, colloidal silicon dioxide (Aerosil 
200®), lactose monohydrate (lactose), microcrystalline 
cellulose (PH 102), magnesium stearate, sodium starch 
glicolate, polyvinylpyrrolidone (PVP) K30, and talc were 
supplied by Henrifarma (Brazil). Eudragit L 30 D 55® 
(Rohm, Germany) and triethyl citrate were supplied by 
Almapal (Brazil). Simethicone (Dow Corning®, Belgium), 
titanium dioxide and polysorbate 80 were supplied by 
Gerbras (São Paulo, Brazil). 
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Plant material
Powdered aerial parts of T. parthenium were pur-
chased from Galilee Herbal Remedies (Kibbutz Kfar 
Hanassi, Israel) and submitted to several analyses in order 
to certificate its authenticity (Chaves, Da Costa, 2008).
Preparation of feverfew hydroalcoholic extract 
The hydroalcoholic extract was obtained by percola-
tion of the T. parthenium powder in 70% ethanol according 
to the German Pharmacopoeia specifications, described 
by List and Schmidt (1989). Two parts of the extract were 
obtained from one part of the powder. This process was 
performed in three steps: 1) pre-swelling for 2 h with a 1:3 
solvent to powder proportion; 2) intermediate maceration 
(24 h); 3) percolation (4–6 drops/min) per 100 g of powder 
(List, Schmidt, 1989).
Spray drying of extracts
The T. parthenium spray-dried powder was prepa-
red from a suspension containing 55% of hydroalcoholic 
extract (w/w), 40% of water (w/w) and 5% of colloidal 
silicon dioxide. During the atomization procedure, the 
mixture was mixed with a magnetic stirring bar. The 
suspension was dried using a mini spray-drier model LM 
MSD 1.0 (Labmaq do Brasil Ltda., Brazil) with capacity 
of drying up to 1.0 litre per hour. The atomization was 
carried out with a two-fluid 1.2 mm pneumatic nozzle, and 
the dryer was operated in concurrent flow. A summary of 
operational conditions employed during spray-drying is 
shown in Table I.
Tablet compaction and coating
Tablets were obtained by a direct compression me-
thod in an eccentric compression machine (Fabbe®, Brazil) 
using an 8 mm bi-concave punction regulated to obtain 
tablets of 200 mg. Excipients (Table II) were sieved and 
mixed in a geometric order. The spray-dried extract was 
mixed with sodium starch glicolate, cellulose and lactose. 
The magnesium stearate was mixed with talc and colloidal 
silicon dioxide, followed by PVP. Finally, the components 
were mixed thoroughly.
The tablets were coated in a lab scale Wurster bed 
coater model SBC 1.0 (Labmaq do Brasil Ltda., Brazil) 
with capacity of up to 1.0 kg of tablets. The equipment 
is a bottom spray fluid bed coater. The coating suspen-
sion (Table III) was applied in a proportion of 4:1 (w/v) 
tablets:suspension. The coating operational conditions 
are summarized in Table IV. The suspension components 
were mixed in a high shear mixer at 13,500 rpm during 5 
min. Then, Eudragit® L30 D55 was added and the mixture 
was stirred with a magnetic bar at 50 rpm for 1 h (Kfuri, 
Freitas, 2006).
Quantitative analysis of parthenolide
The parthenolide content was determined by HPLC 
according to a previously reported method (Chaves, Da 
Costa, 2008). In summary, the stock solution of partheno-
TABLE I - Summary of operational conditions during spray 
drying of extracts
Operational factor Value
Air flow rate, m3/min 0.60
Air inlet temperature, oC 100
Air outlet temperature, oC 60
Extract feed rate, mL/min 1.5
Nozzle air pressure, kgf/cm2 4.0
Nozzle air flow, L/min 40
TABLE II - Composition of tablets containing feverfew spray-
dried extract
Components %
Polyvinylpyrrolidone (PVP) K30 5
Aerosil® 1
Microcrystalline cellulose PH 102 44.03
Sodium starch glicolate 3
Magnesium stearate 2
Lactose 14.68
Talc 3
T. parthenium spray-dried extract 27.29
TABLE III - Composition of coating suspension for the feverfew 
tablets
Formulation % 
Eudragit L30 D55® 15.0 
Simethicone 0.5
Polissorbate 80 0.6
Talc 3
Titanium dioxide 1.5
Triethylcitrate 2.1
Water 100.0 q.s. ad.
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lide was prepared dissolving 5 mg of parthenolide in 5mL 
of acetonitrile (CH
3
CN). Standard solutions with concen-
trations of 1, 2, 10, 50, 100, 250, 500, and 750 μg mL were 
prepared from the parthenolide stock solution (1 mg/mL) 
by means of sequential dilution with CH
3
CN. 150 mg of 
the T. parthenium spray dried powder were extracted with 
10 mL of CH
3
CN:H
2
O 9:1 (v/v), sonicated for 30 min 
and centrifuged for 12 min. The supernatant was passed 
through a 0.45 μm nylon membrane (Sartorius, Spain). The 
injection sample volume was always 20 μL. The analyses 
were performed in triplicate and the parthenolide content 
was calculated on the basis of the peak area against a 
calibration curve prepared by injecting standard solutions 
(Chaves, Da Costa, 2008).
Detection of santin in spray-dried extract
The santin content was determined by HPLC accord-
ing to a previously reported method (Chaves, Da Costa, 
2008). A clean-up step with a C-18 Sep-Pak cartridge 
(Waters Association, Milford, USA) was used to remove 
interfering material of the T. parthenium spray dried 
powder. The cartridge was preconditioned with 5 mL of 
methanol and 5 mL of water. An aliquot of the extract (1 g) 
was mixed with 2 mL of ethanol and eluted with 10 mL 
of methanol 60%. The solvent was evaporated and the 
residue was suspended in 1 mL of methanol 60%. Santin 
was suspended in 1mL of methanol 60% (1 mg/mL). The 
samples were filtered through a 0.45 μm nylon membrane 
and directly injected into the HPLC system. Injection 
volume was 50 μL.
Total flavonoid content of spray-dried extract 
The determination of total flavonoid content was 
carried out using a UV spectrophotometer model Kayak 
XA (Hewlett Packard, USA), according to the method 
described in the German Pharmacopoeia (De Paula, 1996). 
Analyses with samples of 0.4 g were performed in tripli-
cate. The following formula was used to calculate the total 
flavonoid content:
TF = A . fd / 500 . p . (100 – t), where:
TF = total flavonoids calculated using quercetin as refe-
rence (%; w/w)
A = absorbance
p = weight (g)
t = loss on drying (0.41 %)
fd = dilution factor (62500)
Particle size measurements 
The determination of particle size of the spray-
dried powder was performed using an optical microscope 
(Olympus BX 60) coupled with an image capture system 
(Sony CCD-Iris, Japan). The powder was homogeneously 
dispersed on a slate using a vacuum device (vacuum-
gage PD-10, Galai). The average particle diameter was 
calculated using the software Image Pro-Plus® (Media 
Cybernetics Inc. All®, USA). The analyses were perfor-
med in triplicate, counting 270 to 300 particles in each 
measurement.
Angle of repose
The powder sample was put carefully in a funnel 
with bottom stem of 4.5 mm internal diameter. The powder 
was allowed to flow freely and the diameter and height 
of the mound formed were measured (Swarosky, 1987). 
The analyses were performed in triplicate and the angle 
of repose was calculated by the arc tangent of the ratio of 
mound height to radius.
Tapped density
The powder (2.5 g) was carefully placed into a 
25 mL graduated cylinder. The cylinder was tapped 200 
times and the powder volume was measured at every 20 
taps. This procedure was repeated three times (Kawashima 
et al., 1988).
Hygroscopicity evaluation
Spray-dried powder moisture uptake was deter-
mined using a method modified from the one described 
by Senna et al. (1997). Powder samples (300 mg) were 
conditioned at 25 oC ± 1 oC in four airtight glass flasks 
with different saturated salt solutions in water (magnesium 
chloride hexahydrate, potassium carbonate, sodium nitrate 
TABLE IV - Operational conditions for fluid bed coating of 
feverfew tablets.
Factors
Tablet, mg 200
Coating preparation see Table III
Coating suspension feed rate, mL/min 1.5
Spray nozzle air rate, L/min 50 
Spray nozzle air pressure, kgf/cm2 2 
Fluidizing air temperature, oC 45 
Fluidizing air flow rate, m3/min 0.26
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and zinc sulphate), corresponding to 33, 43.2, 64.5 and 
90% relative humidity, respectively. The sample moisture 
content was gravimetrically determined at 24 h intervals 
during a 10-day period. These experiments were carried 
out in duplicate.
Scanning electronic microscopy (SEM)
The morphology of the spray-dried powders was 
evaluated by scanning electron microscopy (Field Emis-
sion Gun Philips 3000®) at magnifications of 500, 1,000, 
2,000 and 10,000x. Before the SEM, the samples were 
coated with gold/palladium under argon atmosphere using 
a Balzers evaporator (SCD 050, Bal-Tec, AU).
Moisture content
The residual moisture content of the spray-dried ex-
tracts was determined by weight loss in an oven at 105 oC 
for 5 h using samples of 300 mg (Farmacopéia Brasileira, 
2000). Analyses were performed in triplicate.
Parthenolide soluble content
The parthenolide soluble fraction in the spray-dried 
powder was determined by dissolving it at 12 different 
concentrations (20 – 100 mg/mL) in phosphate (pH 7.5) 
and hydrogen chloride (pH 1.2) buffers. Samples were 
stirred for 48 h, at 37 oC and 500 rpm (Swarosky ,1987), 
filtered using 0.45 μm membranes and then analyzed by 
HPLC (see Quantitative analysis of parthenolide).
Evaluation of uncoated and coated tablets 
The average weight, hardness, friability and disinte-
gration time of the uncoated and coated tablets were deter-
mined according to the methods described in the Brazilian 
Pharmacopoeia (1988). The hardness was determined 
using a Tablet Tester 8M, the friability was measured with 
an Ética 300.1 friabilator and the disintegration time was 
measured in purified water at 37 ± 0.5 °C, in an Ética 301 
AC apparatus.
Dissolution of coated tablets
The coated and uncoated tablets containing 0.2% 
of parthenolide were inserted into dialysis bags which 
were subsequently immersed in flasks containing 10 mL 
of phosphate buffer pH 7.4 under magnetic stirring at 
100 rpm and 37 oC. This procedure was adopted to gua-
rantee that the dissolution test would be adequate for both 
sink conditions and the detectable range of parthenolide 
by the HPLC methodology adopted herein. Samples were 
collected at every 15 min for a 2 h period and then analyzed 
by HPLC (see Quantitative analysis of parthenolide). 
RESULTS AND DISCUSSION
Parthenolide quantification and flavonoids 
analyses
The grinded herb contained 0.49% of parthenolide 
and 0.54% of total flavonoids. The hydroalcoholic extract 
presented total flavonoid and parthenolide and total solid 
contents of 1.05, 1.06 and 10.8%, respectively. The total 
flavonoid and parthenolide contents in spray-dried extracts 
were 1.31% and 0.76% (w/w), respectively, with relative 
standard deviations (RSD) of 6.9% and 1.6% (Table V). 
The low RSD obtained for triplicate quantifications de-
monstrate the adequacy of the methods. 
According to literature, ethanol extracts should 
be prepared with ethanol and water and contain 70% or 
less of alcohol. In this work the alcohol 70 was chosen to 
prepare the extract by percolation because it showed the 
better extraction of parthenolide than other alcohol/water 
mixtures (data not shown).
The analysis of parthenolide from the spray-dried 
extract and solid dosage form are important to evaluate the 
overall process efficiency and reproducibility because this 
metabolite can undergo thermal or chemical degradation 
during the process. Furthermore, these metabolites are 
essential for the pharmacological effects of T. parthenium 
(Williams et al., 2003). The HPLC/DAD chromatograms 
obtained for parthenolide and spray-dried extract are sho-
wn in Figures 1A and 1B, respectively. The chromatogram 
TABLE V - Chemical, physical and physicochemical properties 
of feverfew spray-dried extract
Assay Result RSD, % Literature data
Total flavonoids content 1.31 6.9 -
Parthenolide content 0.76 1.6
0.1 % - 0.2 %, 
Palevitch et al. 
(1997)
Bulk density
0.3846
 g/mL
0 -
Moisture content 0.41% 8.5 -
Angle of repose 35.7o 0.8 -
*RSD = relative standard deviation = (standard deviation/
average) x100
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in Figure 1B demonstrates the excellent resolution of the 
method for parthenolide, which was detected at 210 nm 
after a retention time of about 15 min (in the middle of the 
chromatogram).
The calibration curve was obtained for the peak area 
as a function of the standard concentration in the solution 
(μg/mL). The variation coefficients ranged from 0.23 to 
3.7% (data not shown). Analyses of UV spectra collected 
at the beginning, in the middle and at the end of the parthe-
nolide peak showed that the method presents specificity. 
The quantification limit was 0.07 μg (70 μL of a 1 μg/mL 
solution) and the detection limit, based on three times the 
noise level, was 0.02 μg (20 μL of a 1 μg/mL solution). 
Acceptable intra and inter-assay precision were obtained 
for the method since the % RSD ranged from 0.34 – 4.1% 
for the intra-assays and 0.34 – 2.19 % for the inter-assay 
precision tests (data not shown). The accuracy ranged 
from 94.09 – 99.99 (data not shown). These results de-
monstrate that the HPLC and sample extraction methods 
were reproducible.
Figures 2A and 2B present the HPLC/DAD chro-
matograms for flavonoid santin and the spray-dried ex-
tract, respectively. Santin was detected at 241 nm after 
a retention time of about 4 min, and Figure 2B shows 
that a good resolution was obtained under the applied 
conditions. Besides the analysis of santin, experiments 
were performed in order to determine the total flavo-
noid content by spectrophotometry using quercetin as 
reference.
Pharmacological investigations of feverfew and 
parthenolide have demonstrated that both present 
anti-inflammatory effect through the inhibition of 
eicosanoids as well as the transcription nuclear kappa-B 
(NF-kB) (Gruenwald et al., 2000; Garcia-Piñeres et al., 
2001; 2004). Further studies revealed that flavonoids 
such as santin are also important anti-inflammatory 
constituents of this species (Long et al., 2003; Williams 
et al., 1999).
Although parthenolide as well as feverfew have 
been subject to several chemical and pharmacological 
investigations, a study describing the standardization of its 
dried including flavonoids analysis as well as parthenolide 
quantification was still lacking.
FIGURE 1 - HPLC/DAD chromatograms of parthenolide 
analyses, mAU x Time (min): (A) parthenolide standard; (B) 
spray-dried extract from feverfew. Mobile phase: acetonitrile: 
water (45:55). Flow-rate: 1 mL/min. Detection at 210 nm.
FIGURE 2 - HPLC/DAD chromatograms of santin, mAU x 
Time (min): (A) santin standard ; (B).spray-dried extract from 
feverfew. Mobile phase: solvent A (2% formic acid in water); 
solvent B (Acetonitrile). Gradient elution 0-10 min 15% B in 
A; 10-40 min 15-30% B in A and 40-50 min 30-15% B in A. 
Flow-rate: 0.8 mL/min. Detection at 241 nm.
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Characterization of the spray-dried extract
Before spray drying, the liquid extracts were diluted 
in water to increase their fluidity and reduce the ethanol 
content, preventing explosion hazards and nozzle blocking 
during the atomization. The addition of colloidal silicon 
dioxide in the liquid extract reduces the adherence of the 
material to the equipment walls and improves the dry po-
wder shape (spherical), size distribution and flowability 
(Runha et al., 2001).
Figure 3 presents the scanning electronic microsco-
py (SEM) of the spray-dried extract powder showing that 
the particles are spherical in shape, which is a common 
feature of the spray drying process. The particles sphericity 
is one of the advantages of spray-dried pharmaceutical 
powders, since this shape is associated with adequate flo-
wability and bulk density. The results on particle size me-
asurements (PSM) are shown in Figure 4, representing the 
cumulative size distribution. The PSM in Figure 4 showed 
that the powder sizes are homogenously distributed, and 
the cumulative size distribution fits to the Rosin-Rammler 
distribution with an acceptable squared correlation coeffi-
cient (R2 = 0.9976). The average diameter based on 50% 
cumulative weight was 4μm.
Other important physicochemical properties of the 
spray-dried powder are presented in Table V. The “poured” 
angle of repose was 35.7o, which can be related to “inter-
mediate” powder flow properties. Considering that this 
powder is obtained from a plant extract it is expected to 
have angle of repose higher than 30o (Endale et al., 2002; 
Stariff et al., 2007; Von Eggelkraut et al., 2002).
The dried extract presents low bulk density and 
moisture content, which are indicatives of good fluidity 
and chemical/microbiological stability, respectively. The-
se properties are essential for the development of tablets 
(Senna et al., 1997).
Besides the determination of spray-dried extract 
moisture content, their hygroscopic properties were also 
determined by water uptake under different relative hu-
midity conditions. The curves of water uptake or powder 
weight gain as function of time obtained for the relative 
humidity of 33, 43, 65 and 90% are shown in Figure 5. As 
can be seen, except at the relative humidity of 90%, the 
spray-dried extracts showed very low water adsorption 
during the entire experiment (240 h). This can be explained 
by the non-hygroscopic characteristic of the drying aid 
used (colloidal silicon dioxide). However, under extreme 
relative humidity conditions (90%), the powder absorbs 
water in the initial 72 h and then the moisture content 
remains constant, attaining the balanced moisture content.
The solubility of parthenolide from the spray-dried 
extract was assayed in phosphate buffer solution pH 7.5 at 
different powder concentrations, as presented in Figure 6. The 
graph demonstrates that there is a maximum in the percentage 
of parthenolide solubilised for the concentration of 50 mg/mL 
of spray-dried extract. However, in all concentrations only a 
fraction, 25 to 40%, of parthenolide was solubilized.
FIGURE 3 - SEM micrographs of feverfew spray-dried extract 
(x 10,000, 2,000).
FIGURE 4 - Cumulative particle size distribution of spray-dried 
extract from feverfew, average diameter (mm) x accumulated 
fraction (RRD model, R2 = 0,9976).
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Experiments were also run to determine parthenolide 
solubility in HCl buffer pH 1.2, but the amounts solubilized 
were not detectable by HPLC/DAD (data not shown). Based 
on these results, experiments were carried out to determine 
the dry extract n-octanol-water partition coefficient (log 
P). Nevertheless, it was not possible to determine this 
parameter since parthenolide was almost entirely found in 
the n-octanol phase. These results suggest that the feverfew 
pre-formulation may be absorbed through the intestinal 
mucosa. Previous work showed that parthenolide is effec-
tively absorbed through the intestinal mucosa via a passive 
diffusion mechanism (Khan et al., 2003).
Recently, there has been an increasing interest in dry 
extracts of natural products. The dry extracts present ob-
vious advantages in pharmaceutical formulations, such as 
the possibility of easy preparation of tablets and capsules 
and better conditions of stability. Moreover, we showed 
that the content of parthenolide and total flavonoids in the 
spray-dried extract of T. parthenium are higher than the 
powder of the plant (Chaves, Costa, in Press)
Feverfew tablets
The properties of the feverfew dry extract presen-
ted in the previous section demonstrated that it is fairly 
adequate for direct compression, although this is not 
the usual characteristic of dry herbal extracts (Palma et 
al., 2002). The direct compression method is faster and 
simple, but requires the use of excipients with good flow 
and compressibility properties, such as microcrystalline 
cellulose PH 102, PVP 30, magnesium stearate and colloi-
dal silicon dioxide. The amount of spray-dried extract in 
tablets was established according to literature information 
of parthenolide therapeutical doses, ranging from 0.1 to 
0.4 mg daily (Gruenwall et al., 2000). The formulation in 
this work presents a total parthenolide content of 0.4 mg. 
The formulation used is shown in Table II, and during the 
whole compression process it showed none of the proble-
ms associated with unsatisfactory tableting. 
Some important properties of the tablets obtained are 
presented in Table VI, demonstrating that the cores have 
adequate hardness, friability and weight uniformity. On 
the other hand, the tablets rapidly disintegrate in simulated 
gastric fluid (8 min).
The previous reports on gastrointestinal irritation, 
abdominal pain and heartburn of feverfew preparations 
(Johnson et al., 1985; Murphy et al., 1988; O’Hara et al., 
1998) indicate that enteric coating of the solid dosage 
form to allow release only in the intestine would be more 
adequate. Aqueous polymeric dispersions have gained po-
pularity and are replacing solvent-based systems due their 
lower toxicity level and environment friendly standpoint. 
Acrylate polymers and their derivates such Eudragit L30 
D-55 Ò in a form of aqueous dispersion are widely used in 
the pharmaceutical industry as coating materials (Zhang 
et al., 2007)
The spouted bed and its variants have been exten-
sively studied for diverse unit operations such drying of 
granules and pastes and particle coating. In the pharma-
ceutical field, spouted bed coating has been used for ta-
blets, capsules and granule coating with excellent results 
(Kfuri, Freitas, 2006) The recent development of the new 
aqueous polymeric emulsions for pharmaceutical coating 
has generated interest in alternative equipment, since the 
traditional pan coaters were shown to be ineffective in this 
case, due to their low aeration profiles and consequently 
low drying capacity. Fluidized and spouted beds have been 
the choice to overcome this limitation, due to their high 
level of aeration and good gas-solid contact. The previous 
FIGURE 5 - Moisture uptake of the spray-dried extract from 
feverfew (humidity as a function of time). 
FIGURE 6 - Parthenolide soluble content in phosphate buffer pH 
7.4 of feverfew spray-dried extract, spray powder concentration 
(mg/mL) x parthenolide content (%). 
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studied published by our group (Kfuri, Freitas, 2006) sho-
wed that the fluidized bed conditions used here, presented 
good coating quality without problems of agglomeration, 
picking or any other factor related to poor drying condi-
tions and that these operational conditions can be applied 
for the coating of tablets. 
The properties of coated tablets can be seen in TA-
BLE VI, showing an increase in hardness and decrease 
in friability, as expected for Eudragit® L30 D55 coated 
cores. The tablets weight variation also decreased, which 
is indicative of the good coating uniformity provided by 
the fluid bed process. The disintegration test showed that 
tablets do not disintegrate in HCl solution, and totally 
disintegrate after 19 min in phosphate buffer. 
According to literature specifications, 70–75% of 
the drug should be released in 45–60 min (United States 
Pharmacopoeia, 1995). However, the release profile can be 
limited by the physicochemical properties of parthenolide, 
such as the low solubility, as well as by the tablet formu-
lation. Due to the poor parthenolide solubility and to the 
limit of detection of the HPLC method used in this work, 
the dissolution test was performed with modifications, as 
detailed in the materials and methods section. The disso-
lution profile is presented in Figure 7.
The dissolution profile demonstrates a linear rate until 
it reaches the maximum amount of parthenolide released in 
approximately 60 min. The linear section of parthenolide 
release, or zero order models, fitted to the dissolution data 
with squared correlation coefficient of 0.9916 and is ade-
quate for this formulation. The release rate was 0.47% per 
minute, which corresponds to 1.88 μg of parthenolide per 
minute. However, due to the already mentioned poor solu-
bility of the parthenolide, only a small fraction (30%) of this 
compound was released during the tests, which corresponds 
to 0.12 mg of parthenolide. The tablet formulation based on 
the feverfew spray-dried extract was demonstrated to be 
adequate for this phytomedicine.
CONCLUSIONS
The procedures described herein can be used to 
prepare and evaluate a pre-formulation of feverfew with 
essential properties for the development of a high-quality 
phytomedicine. The spray-dried extract demonstrated 
adequate properties, such as particle size and shape, bulk 
density, flowability, and compressibility. Furthermore, 
it was possible detect parthenolide and flavonoids after 
drying process. The characteristics of the tablets obtained 
confirmed the good compressibility of the spray-dried ex-
tract and showed adequate pharmacotechnical properties. 
However, the assays on parthenolide solubility showed that 
efforts should be directed towards the development of T. 
parthenium inclusions or complexes with solubility helpers.
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TABLE VI - Pharmaceutics properties of feverfew tablets
Assay
Results RSD (%) Literature data
uncoated coated uncoated coated
Hardness (kgf) 5.5 11.95 7.70 7.40 4.5 kgf
Friability (%) 0.11 0.19 - - 1.5 %
Weight (mg) 196.05 202.85 3.90 3.30 7.5 % 
Disintegration (min)
pH 1.2 8,00 > 120 - -
pH 7.4 - 19,00 - -
FIGURE 7 - Parthenolide dissolution from feverfew tablets 
in phosphate buffer pH 7.5, parthenolide released (%) x Time 
(min); each symbol represents the average of triplicates.
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